The earlier investment cannot answer the next question
When a development programme reaches a difficult review, the room contains more than the latest evidence. It contains years of work, relationships with research partners and the professional identity of people who believed the question was worth pursuing. A finance leader who begins by calling past spending irrelevant may be correct about one aspect of the investment calculation and still fail to understand the decision. Historical expenditure cannot justify another commitment by itself, but the people and obligations created along the way remain part of the enterprise's responsibility.
At Velmara, one programme reached its planned review without meeting the predefined criterion for the proposed expansion. Scientific leadership did not recommend proceeding on that basis. The company had spent USD31 million over several years, and the next-year expansion proposal required USD16 million. Some colleagues wanted another attempt because they believed there might still be a useful path. That argument deserved examination on its own terms. The amount already spent could explain why the discussion mattered so much, but it could not establish what another dollar of research would help us learn.
I asked the scientific and development leaders to describe the alternatives clearly. Was there a different question that could be answered with the available evidence and resources? Did the proposed work remain capable of answering the original question? What would management do with the possible results? Finance contributed the resource and commitment account while the qualified teams assessed the scientific case. We did not design a smaller study simply to keep a budget line alive. A cheaper activity that could not support the required judgement would have created the appearance of progress without its purpose.
The review did not produce a credible basis for the proposed expansion. The board accepted the recommendation to stop that next step. It was important to describe exactly what had been decided. We were not declaring that every scientific idea associated with the programme had become worthless, nor were we using a finance conclusion to determine participant care. We were choosing not to fund a particular development path on the evidence available. That precision helped preserve the scientific record and prevented a difficult portfolio judgement from becoming a broader claim than the review supported.
Closure is work with owners
Stopping the expansion did not bring the programme's responsibilities to zero. Clinical, legal, records and people teams identified the work that remained. The board approved USD2.6 million for closeout and transition alongside the decision not to fund USD16 million of proposed expansion. Participant follow-up and other clinical obligations stayed with the responsible teams and their requirements. Finance's task was to ensure that the plan contained the resources those responsibilities needed. A stop decision that depended on quietly underfunding the remaining work would not have been a complete decision.
Twenty-two colleagues were affected. Fourteen moved to other programmes and eight left with transition support included in the closeout budget. Redeployment was an operating choice, not a way to make their salary cost disappear. The receiving programmes needed to explain the work and supervision those colleagues would undertake. For those leaving, a respectful process required time and attention from managers as well as a financial provision. We discussed those consequences in the original proposal rather than present a clean expenditure reduction and leave the human implications to be resolved after approval.
The difference between the two defined proposals was USD13.4 million of lower planned spending for the next year. That was not an immediate cash inflow, a recovery of the USD31 million already used or an identical reduction in the company's entire cost base. Payment schedules, continuing commitments and redeployed staff affected the wider plan. I wanted directors to understand the comparison without losing the reason the decision had been made. It was a research portfolio choice informed by evidence, not a cost-reduction programme searching for a scientific justification after the fact.
The team also needed an account of what would be retained from the work. Records, analyses and knowledge can remain valuable even when a proposed development path closes. Their preservation requires ownership; it does not happen automatically because files exist somewhere in the organisation. The appropriate scientific and information teams determined what had to be maintained and how. Finance ensured that the resulting work was not excluded from the budget simply because it did not look like future expansion. The same discipline helped identify contractual matters that needed explicit settlement or continuing administration.
Make a stop possible before it becomes necessary
The experience changed how I prepare for an earlier portfolio review. A programme proposal should identify the decision the funded work is intended to support and the consequences of different outcomes. That does not require pretending to anticipate every possible result. It does require acknowledging that a responsible organisation may decide not to proceed. If the only funded future is continuation, management will face pressure to reinterpret disappointing evidence as a request for another round of expenditure. A credible stopping path gives scientific judgement room to remain honest when the result is unwelcome.
This does not mean finance should make programme teams rehearse failure at every meeting. The purpose of research is to pursue worthwhile questions, and committed teams need confidence that the organisation will support rigorous work. I distinguish confidence in the quality of the effort from certainty about the answer. A company can value its researchers and still decline a particular next investment. The way it treats colleagues after a stop will influence whether future teams believe that distinction. If every negative result becomes a personal indictment, candour will become harder to obtain.
I would now bring the closeout estimate into the review earlier and identify the dependencies that could make it change. A supplier settlement, additional records work or a different redeployment timetable may affect the cost. Those uncertainties should be visible, just as uncertainties in an expansion plan would be. I would also ask for a clear owner of the closure account, so it does not become a collection of residual tasks passed between departments after the main programme team has dispersed. An approved budget is a beginning, not proof that the work has been completed.
For directors, the question is whether management can accept the evidence while honouring the commitments created in obtaining it. The answer requires more than a decision to remove a future spending line. It needs a scientific recommendation, an intelligible comparison of alternatives, a funded account of remaining obligations and a fair description of the consequences for people. In this case, USD2.6 million was part of the discipline of stopping, not a contradiction of it. Research capital is used responsibly when the company can act on what it learns, including an answer that closes a path it once hoped to follow.